top of page

ASH 2025: Aleta Biotherapeutics' Paul Rennert shares the company's first clinical data for its CAR-T cell engager program that is meant to increase the density of CD19 on B-cell malignancies

Dec 8, 2025

1 min read

He describes the data, and walks us through two different dosing strategies. Plus, the business case for this simple biologic, and thinking about other antigens and cancer types.

https://vimeo.com/1144467342?share=copy&fl=sv&fe=ci

Coverage brought to you by

Recent Posts

From Montreal: Congruence Therapeutics uses computational discovery to develop novel small molecule correctors and allosteric modulators - its lead program is for a high profile genetic obesity target

Oxford based Alethio Therapeutics unveiled a $90M Series A today to advance its therapies for myeloproliferative neoplasms, and also announced for the first time that ATX-011's target will be G6B

Oxford based Alethio Therapeutics unveiled a $90M Series A today to advance its therapies for myeloproliferative neoplasms, and also announced for the first time that ATX-011's target will be G6B

From Montreal: Ocythera is developing a treatment for rare bone disorders that targets the retinoic acid pathway without using retinoids

From Montreal: Ocythera is developing a treatment for rare bone disorders that targets the retinoic acid pathway without using retinoids

Follow BiotechTV

Also look for unique social pages for BiotechTV U.

Sponsors

10x_Genomics_logo.svg.png

NYSE_logo_large_no reg_378x197 (1).png

Learn more about our sponsors

Sponsor Spotlight

Mispro is an AAALAC-accredited contract vivarium organization (CVO) offering a network of full-service vivarium rental lab facilities for preclinical in vivo rodent studies. Along with access to state-of-the-art lab spaces, Mispro supports its clients with comprehensive laboratory animal research services, including husbandry, veterinary, technical, and regulatory compliance oversight. With locations in all major U.S. biotech hubs, Mispro is committed to helping biosciences companies of all sizes and therapeutic indications achieve their research goals.

bottom of page